Richard Barry, Director of Cassava Sciences, Increases His Stake in the Company

September 2, 2022

Trending News 🌥️

Cassava Sciences Intrinsic Value – Cassava Sciences($NASDAQ:SAVA), a clinical-stage biopharmaceutical company, announced in a regulatory filing that its director Richard Barry bought 36.16K shares of common stock at $23.79 on Aug.23 for a total outlay of $860K. Some analysts believe that the insider purchase could be a positive sign for the company, as it indicates that Barry is confident in the company’s future prospects. Others believe that the move could be simply a way for Barry to increase his control over the company. Either way, the move is likely to have a positive effect on the company’s share price in the short term. In the long term, it is unclear how this will affect the company’s market and earnings.

Stock Price

On Friday, CASSAVA SCIENCES stock opened at $30.1 and closed at $29.4, up 7.7% from its previous closing price of $27.3. With its strong clinical data and promising outlook, Cassava Sciences is quickly becoming a leading biotech company in the fight against Alzheimer’s disease. And with Richard Barry increasing his stake in the company, it is clear that he believes in the company’s long-term potential.

VI Analysis – Cassava Sciences Intrinsic Value

Investors looking for undervalued stocks may want to take a closer look at Cassava Sciences, Inc . The company’s fundamentals reflect its long term potential, and the fair value of its shares is around $29.9, according to the VI Line. Cassava Sciences is currently trading at $29.4, a fair price that is undervalued by 2%. The company’s strong fundamentals and long-term potential make it an attractive option for investors looking for undervalued stocks.


Cassava Sciences is a clinical-stage biopharmaceutical company focused on developing new treatments for neurological disorders. The company’s lead product candidate is Sumavel DosePro , a needle-free delivery system for the treatment of migraine headaches. This news coincided with a stock price move up the same day. Investors may want to consider investing in Cassava Sciences as the company appears to be making progress in its development of new treatments for neurological disorders. The stock price movement on the news of Mr. Barry’s increased stake in the company also suggests that there is investor interest in the stock.

Recent Posts

Leave a Comment